ICAM-2 has been implicated in leukocyte transmigration in vitro but there is little in vivo evidence to support this. To address this, neutrophil migration was investigated in ICAM-2 deficient mice (KO) and in wild-type (WT) mice treated with an anti-ICAM-2 blocking mAb (3C4). In a peritonitis model, IL-1F-induced accumulation of neutrophils was significantly reduced in mice treated with 3C4 (51% inhibition) and in KO mice (41% inhibition). In contrast, TNFH-or thioglycollate-induced responses were not suppressed in KO mice. Analysis of IL-1F-induced leukocyte responses in cremasteric venules of KO animals by intravital microscopy indicated a defect in transmigration (44% inhibition) but not rolling or adhesion. As found before, TNF -induced leukocyte transmigration was unaltered in the KO mice. WT mice treated with the anti-ICAM-2 mAb also exhibited a selective reduction in leukocyte transmigration in response to IL-1F whilst an anti-ICAM-1 mAb inhibited both leukocyte adhesion and transmigration.
Introduction
The emigration of leukocytes from blood vessels into tissues is a crucial process both during immunosurveillance and inflammation. This response is thought to involve sequential steps of leukocyte rolling, activation, firm adhesion and finally migration through endothelial cells and the vascular basement membrane. These cellular events all require adhesive interactions between leukocytes and endothelial cells/extracellular matrix proteins with the initial intravascular phases being largely mediated by selectins and integrins. The mechanisms that mediate migration through venular walls are less well understood though there is now good evidence for the involvement of a number of junctional molecules in the process of leukocyte migration through endothelial cells [1] [2] [3] . In this context, molecules such as PECAM-1 (CD31), members of the JAM family (in particular JAM-A, -B and -C), CD99, ESAM, ICAM-1 and ICAM-2 have been implicated 2;3 . Though there is much in vivo evidence for the involvement of PECAM-1 in leukocyte transmigration [4] [5] [6] [7] and increasing in vivo evidence for the involvement of the other listed endothelial cell junctional molecules in leukocyte migration in inflammatory models [8] [9] [10] [11] , there is to date no direct evidence for the involvement of ICAM-2 in leukocyte transmigration in vivo, a critical issue that is addressed in the present study.
ICAM-2 is a 55-kDa member of the immunoglobulin superfamily of adhesion molecules composed of two N-terminal Ig domains with 35% homology to ICAM-1, a transmembrane domain and a short cytoplasmic tail of 27 amino acids. This molecule is constitutively expressed on endothelial cells, platelets and most leukocytes. The expression of ICAM-2 on resting endothelial cells is much higher than that of ICAM-1 (10-15 fold) and in contrast to ICAM-1, whose expression is rather uniformly expressed on the surface of endothelial cells, in vitro, ICAM-2 appears to be more concentrated at endothelial cell junctions.
Despite being cloned more than 15 years ago 12 , studies into the functional roles of ICAM-2 are limited though it has been implicated in leukocyte trafficking 13 and immune cell activation 14 , and more recently, in angiogenesis 15 . With respect to leukocyte migration, numerous in vitro studies involving blocking mAbs have indicated a role for ICAM-2 in transmigration of all leukocyte sub-sets through stimulated or un-stimulated HUVECs 13;16;17 . Furthermore, using ICAM-1 and ICAM-2 deficient endothelial cell lines, the relative importance of ICAM-1 in lymphocyte transmigration, as opposed to adhesion, and the co-operative interaction of ICAM-1 and ICAM-2 in lymphocyte transmigration has been demonstrated 17;18 . In vivo studies employing anti-ICAM-1 and anti-ICAM-2 mAbs and ICAM-1 deficient mice have suggested that ICAM-1 and ICAM-2 are functionally redundant in lymphocyte re-circulation through lymph nodes and ICAM-1, but not ICAM-2, is involved in lymphocytes migration into inflamed sites and trapping within non-inflamed lung 16 . However, using an allergic asthma model, ICAM-2 deficient mice exhibited a delayed increase in eosinophil migration in the airway lumen and a prolonged presence of eosinophils in the lung tissue, with no notable decrease in lymphocyte or monocyte accumulation 19 . More recently, a functional blocking anti-ICAM-2 antibody was shown to inhibit leukocyte infiltration in ICAM-1 KO mice in response to bacterial ocular infection 20 . Collectively though limited, the above in vitro and in vivo studies suggest a role for ICAM-2 in leukocyte migration in response to inflammatory stimuli but they also highlight the critical need for further investigations to elucidate the role of ICAM-2 in mediating leukocyte transmigration in vivo.
The absence of direct in vivo evidence for the involvement of ICAM-2 in leukocyte transmigration led us to perform the present study in which we have investigated the role For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From of ICAM-2 in leukocyte transmigration by intravital microscopy using both ICAM-2 deficient mice and a blocking anti-ICAM-2 mAb. Furthermore, the potential synergistic/additive effect of ICAM-2 and PECAM-1 blockade/deletion was investigated.
The findings of this study provide the first direct evidence for the involvement of ICAM-2 in neutrophil transmigration in vivo, a role that appears to be stimulus-specific.
Furthermore, the findings suggest that ICAM-2 can mediate PECAM-1-independent leukocyte transmigration.
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Materials and Methods

Animals
ICAM-2 KO mice, on a 129SV X C57BL/6 mixed background (F2 generation), were generated as previously detailed 19 . 129SV X C57BL/6 mixed background control mice (F2 generation) were generated in house within the animal facilities of Imperial College London on the Hammersmith Campus. Wild-type C57BL/6 mice were purchased from Harlan-Olac Ltd (Bicester, Oxfordshire, UK). PECAM-1 KO mice, backcrossed for 8 generations onto C57BL/6 background were obtained as a gift from Dr. Tak W. Mak (Amgen Institute, Toronto, Canada) 6 . All animal experiments were conducted in accordance with the British Home Office regulations (Scientific Procedures) Act 1986, UK.
Reagents
Recombinant murine IL-1F and TNFH were purchased from Peprotech, London, UK and R&D Systems, Abingdon, UK, respectively. Anti-ICAM-2 Ab (3C4; rat IgG2a) and the isotype control Ab (rat IgG2a) were obtained from BD Biosciences, San Diego, USA.
Anti-ICAM-1 Ab (YN-1, rat IgG2b) was generated in house from hybridoma cells and a corresponding IgG2b control antibody was obtained from Serotec Ltd (Kidlington, Oxfordshire, U.K). Ketamine (Ketalar) was from Parke Davis (Eastleigh, Hants, U.K) and Xylazine (Rompun) was from Bayer Plc (St. Edmunds, Suffolk, UK). Thioglycollate, Saponin, Toluidine blue, Light Green SF Yellowish, Giemsa, May-Grünwald were all purchased from Sigma Chemical Company (Dorset, UK).
Quantification of leukocyte migration into the peritoneal cavity
Age-matched female mice (WT or ICAM-2 KO, >20g) were injected with intraperitoneal phosphate buffered saline (PBS) (1ml, control group), IL-1F (10ng/ml/cavity), TNFH (100ng/ml/cavity) or thioglycollate (4% solution in 1ml of PBS). In some experiments, 15 minutes prior to the intraperitoneal injection of IL-1F, mice (WT, ICAM-2 KO or PECAM-1 KO) were injected intravenously with saline, anti-ICAM-2 mAb (3C4) or an appropriate control mAb (all at 3mg/kg). Four hours after the injection of intraperitoneal stimuli, the animals were killed by asphyxiation with CO 2 and the peritoneal cavity was opened via mid-line incision and lavaged with 3-5 mls of modified PBS (containing 0.25% bovine serum albumin (BSA) and 2mM EDTA). To quantify the number of neutrophils in peritoneal exudate samples, two staining steps were conducted. Initially total cell counts were determined following staining of peritoneal samples with Kimura stain 21 . Smears of peritoneal samples were then prepared in a cytocentrifuge (Cytospin-3, Shandon, Cheshire, UK), stained with May-Grünwald/Giemsa stains and the number of neutrophils/500 cells counted was measured. These quantifications were used to calculate the number of neutrophils recovered from each cavity. The dose of the anti-ICAM-2 mAb and the cytokines employed were based on preliminary studies aimed at identifying optimal dosing regimes (data not shown) and/or previous studies 
Intravital microscopy
Intravital microscopy on the mouse cremaster muscle was performed as previously 
Immunofluorescent staining of tissues
Cremaster tissues were dissected away from WT and ICAM-2 KO mice and fixed in 4% paraformaldehyde (PFA) before being immunostained for ICAM-2 and PECAM-1 using a modified version of the protocol previously detailed 24 . Briefly, tissues were blocked and permeabilised in PBS containing 20% fetal calf serum and 0.5% Triton X-100. After incubation with the rat anti-mouse mAb 3C4 against ICAM-2 (BD Bisosciences, Oxford, UK) the tissues were washed in PBS, followed by incubation with a goat anti-rat Alexa-Fluor-488-conjugated secondary antibody (Molecular Probes, Eugene, OR). The tissues were thoroughly washed and incubated with a directly allophycocyanin (APC)-conjugated rat anti-mouse mAb Mec13.3 against PECAM-1 (BD Bisosciences, Oxford, UK). After a series of further washings with PBS, samples were mounted on glass slides and viewed using a Zeiss LSM 5 PASCAL confocal laser-scanning microscope (using a x40 water dipping achroplan objective with a numerical aperture of 0.75) equipped with Argon (excitation wavelength: 488nm) and HeNe (excitation wavelength: 543nm) lasers.
Multiple optical sections of tissue samples were captured at room temperature and imaged using the software's automatic scanning mode. Finally, Z-stack images (collected at every 1.2µm depth) were saved and used for 3D-reconstruction analysis using the LSM 5 Pascal software (version 3.2; Carl Zeiss Ltd, Welwyn Garden City, UK).
Statistics
All results are expressed as mean ± SEM. Statistical significance was assessed by Student's T-test or by one way analysis of variance with Neuman-Keuls multiple comparison test. P<0.05 was considered significant.
Results
Antibody blockade or genetic deletion of ICAM-2 suppresses neutrophil migration in vivo
In initial studies, the functional role of ICAM-2 in neutrophil migration in vivo was investigated by using an anti-ICAM-2 Ab, 3C4 and ICAM-2 deficient mice in an IL-1F-driven peritonitis model 22 . Administration of IL-1F (10ng/cavity; 4hr in vivo test period) via the peritoneal route induced a significant increase in neutrophil accumulation into the cavity of WT control mice as compared to mice injected i.p with PBS. This response was significantly suppressed in mice injected with 3C4 ( Figure 1 , 50.6%, inhibition, p<0.05) but not in control Ab treated mice. A similar profile of suppression of neutrophil migration was also observed in ICAM-2 deficient mice (41% inhibition, p<0.05). Of importance, injection of the anti-ICAM-2 mAb 3C4 into ICAM-2 deficient mice had no effect on the IL-1F-induced response in these mice indicating the specificity of this mAb for its antigen. Together, using both an anti-ICAM-2 mAb and ICAM-2 deficient mice, the above findings indicated a functional role for ICAM-2 in mediating neutrophil migration in vivo.
ICAM-2 mediates neutrophil migraton in a stimulus-specific manner
As we have previously found that PECAM-1-mediated neutrophil transmigration is stimulus-specific 7, 23 , we next investigated whether the same phenomenon applied to ICAM-2. For this purpose, neutrophil migration into mouse peritoneal cavities was investigated in response to IL-1F (10ng/1ml/cavity), TNFH (100ng/1ml/cavity) and thioglycollate (4% solution in 1ml PBS) in WT and ICAM-2 deficient mice. As shown in Figure 2 , all three stimuli when injected i.p induced a significant increase in neutrophil migration in WT mice over a 4 hr test period, as compared to mice injected with i.p PBS.
As previously found (Figure 1 ), the response induced by IL-1 F was suppressed in ICAM-2 KO animals, however, the responses induced by TNFH or thioglycollate were unaltered in ICAM-2 deficient mice, indicating their independence of ICAM-2.
ICAM-2 mediates leukocyte migration in vivo at the level of transmigration
To determine the precise stage in the process of leukocyte emigration at which ICAM-2 was involved, in the following series of experiments the role of ICAM-2 in leukocyte emigration through cremasteric venules was investigated, as directly observed by intravital microscopy. The thin and translucent nature of the murine cremaster muscle also makes this model suitable for analysis of vascular expression of adhesion molecules by immunofluorescent labelling and confocal microscopy. As can be seen in Figure 3A 
Blockade of ICAM-2 inhibits neutrophil migration in PECAM-1 KO mice
As the results so far have highlighted numerous similarities between ICAM-2 and PECAM-1, in a final series of experiments we sought to investigate the potential additive/cooperative roles of these molecules. For this purpose, the effect of mAb 3C4 was investigated on neutrophil migration in both WT and PECAM-1 deficient mice as induced by IL-1F in the cremaster muscle and peritonitis models (50ng/mouse i.s. or 10ng/mouse i.p., respectively, using a 4hr test period in both). In both models, as previously found (Figures 1 and 4) , anti-ICAM-2 mAb suppressed leukocyte transmigration and PECAM-1 deficient mice exhibited reduced levels of transmigration 7;22 , indicating ICAM-2 and PECAM-1 dependency, respectively. However, treatment of PECAM-1 KO mice with the anti-ICAM-2 mAb did not result in a greater level of inhibition of neutrophil transmigration through IL-1F-stimulated cremasteric venules to that seen in untreated PECAM-1 KO mice or PECAM-1 KO mice treated with a control mAb ( Figure 5 ). In contrast, using the peritonitis model, the anti-ICAM-2 mAb induced a significant suppression of neutrophil migration induced by IL-1F in PECAM-1 deficient mice. Collectively these data suggest that ICAM-2 may mediate PECAM-1 independent neutrophil transmigration in the peritonitis model but not in the cremaster muscle model.
Discussion
In vitro studies have implicated ICAM-2 in leukocyte transendothelial cell migration but to date there exists no direct in vivo evidence to support this notion. The aim of the present study was to address this issue by the use of both an anti-ICAM-2 mAb and ICAM-2 deficient mice. Collectively, the findings provide direct evidence for the involvement of ICAM-2 in neutrophil transmigration in vivo, an effect that appears to be stimulus-specific. Furthermore, by investigating the effect of a blocking anti-ICAM-2 mAb in PECAM-1 deficient mice, we report for the first time that ICAM-2 can mediate PECAM-1-independent leukocyte transmigration.
Historically, the differential patterns of expression of ICAM-1 and ICAM-2 on endothelial cells and the differences in their inducibility by inflammatory mediators has suggested specialized roles for these molecules in the context of leukocyte trafficking.
Specifically, since ICAM-1 is expressed at low to moderate levels on resting endothelial cells and its expression is up-regulated by inflammatory cytokines, ICAM-1 has been implicated in regulation of leukocyte migration under inflammatory conditions and indeed there is now much evidence to support this 17;18;25-27 . In contrast, the relatively high constitutive expression of ICAM-2 on endothelial cells (specially on high endothelial venules) and the inability of inflammatory mediators to further enhance this expression, for a long time led to the conception that ICAM-2 mediates steady-state recirculation of lymphocytes. Recent in vivo data using both blocking mAbs and ICAM-2 deficient mice has however shown that this is not the case 16;19 . Indeed increasing in vitro data indicating a role for ICAM-2 in lymphocyte, monocyte, eosinophil and neutrophil transmigration through cultured endothelial cells 17, 18, 19, 25, 26, 27 suggests a role for ICAM-2 With respect to PECAM-1, since leukocyte transmigration is highly dependent on the ability of PECAM-1/PECAM-1 interaction to activate leukocyte integrins 22 , it is hypothesized that stimuli that can directly stimulate leukocytes and hence activate their integrins can induce leukocyte transmigration in a PECAM-1-independent manner, ie the need for PECAM-1-mediated integrin activation is by-passed. However at present there is no evidence to suggest that ICAM-2-mediated transmigration is regulated through integrin activation (unpublished observations) and indeed, in contrast to PECAM-1 and as detailed above, in the context of leukocyte/endothelial cell interaction the principal ligands for ICAM-2 appear to be integrins 28, 29, 30 . Furthermore, since it seems that JAM-A-dependent transmigration also exhibits a similar stimulus-specific profile, ie IL-1 -induced leukocyte transmigration is JAM-A-dependent but leukocyte transmigration elicited by chemoattractants such as LTB 4 and PAF is JAM-A-independent (Woodfin et al., manuscript in preparation), a more generalized hypothesis needs to be considered. At present, collectively the available data suggests that stimuli that activate endothelial cells (eg IL-1 ), recruit adhesion pathways involving endothelial cell junctional molecules (eg PECAM-1, ICAM-2 and JAM-A), whereas stimuli that can directly stimulate leukocytes (eg TNF , FMLP, LTB4) appear to by-pass the need for such molecules. Whilst the underlying mechanism associated with these findings is currently unknown, the findings further highlight the existence of stimulus-specific adhesion pathways that mediate leukocyte transmigration. This may account for some apparent contentious and/or inconsistent reports with respect to the potential involvement of specific adhesion molecules in regulation of leukocyte migration in different inflammatory models in vivo.
Although there is now increasing in vitro and in vivo evidence illustrating the involvement of individual endothelial cell junctional molecules in the process of leukocyte transendothelial cell migration, very few studies have addressed the potential additive/synergistic effects of multiple molecules. One such study is by Schenkel and colleagues in which an anti-PECAM-1 mAb was found to act in an additive manner with a CD99 blocker to inhibit monocyte transendothelial cell migration in vitro 31 . Since in numerous inflammatory models PECAM-1 blockade/deletion results in partial suppression of leukocyte transmigration, in a final series of experiments we aimed to investigate the possibility that ICAM-2 may mediate PECAM-1-independent leukocyte transmigration. For this purpose the effect of the anti-ICAM-2 mAb, 3C4, on leukocyte transmigration in WT and PECAM-1 deficient mice was directly compared using both the cremaster muscle and peritonitis models. In line with data discussed above, pretreatment of WT mice with mAb 3C4 resulted in a significant inhibition of neutrophil transmigration in response to IL-1 in both models. However, in PECAM-1 deficient mice although a significant suppression of IL-1F-induced leukocyte transmigration was noted in both in vivo models (in agreement with previous data) 22 , the anti-ICAM-2 mAb, 3C4, appeared to have no additional inhibitory effects in the cremaster muscle but significantly inhibited migration in the peritonitis model. This may suggest that the PECAM-1-independent neutrophil transmigration detected in the cremaster muscle model is also ICAM-2-independent. In contrast, the PECAM-1-independent response in the For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From
